On Oct 31, major Wall Street analysts update their ratings for $Incyte (INCY.US)$, with price targets ranging from $80 to $97.
Citi analyst David Lebowitz maintains with a buy rating, and adjusts the target price from $92 to $97.
TD Cowen analyst Marc Frahm maintains with a buy rating, and maintains the target price at $80.
Oppenheimer analyst Jay Olson maintains with a buy rating, and adjusts the target price from $81 to $82.
Truist Financial analyst Srikripa Devarakonda maintains with a hold rating.
JMP Securities analyst Reni Benjamin maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Incyte (INCY.US)$'s main analysts recently are as follows:
Incyte's third-quarter results showcased topline revenue surpassing expectations, fueled by the enduring growth of essential franchise components like Jakafi and Opzelura. The solid commercial performance, diminishing worries about Jakafi's rivals, and a robust pipeline with multiple opportunities reinforce the company's underlying narrative.
The firm previously held reservations about competitive pressures to Jakafi in myelofibrosis, yet acknowledges that the strong ongoing demand suggests diminished risk currently. They also note optimism driven by the sustained growth of Opzelura, including the potential for its expansion into pediatric atopic dermatitis.
The company demonstrated a robust commercial quarter, showcasing the resilience and strength of its core business despite seasonal challenges and competitive pressures. This performance is anticipated to sustain momentum and enhance investor sentiment as the company approaches several significant updates in the first half of fiscal year 2025.
The company achieved a top-line surpass and provided updated guidance for FY24 that remained steady to improved. This was despite expectations for Jakafi being counterbalanced by a reduced projection in the Heme/Oncology division. Nonetheless, the long-term prospects for the company remain uncertain, especially considering the anticipated impact on revenue from the pipeline following the Jakafi exclusivity expiration slated for 2028.
Incyte has exhibited impressive third-quarter performance, surpassing expectations with a robust top line propelled by Jakafi and Opzelura, alongside a commendable bottom line. In light of this strong commercial execution, the company has elevated its forecast for FY24, hinting at promising Q4 sales for Jakafi and a 6% year-over-year expansion for the subsequent fiscal year. It is anticipated that the industry focus will transition towards pipeline projects, as multiple imminent catalysts are on the horizon, including updates on the LIMBER program, proof of concept data for MRGPRX2 Phase 1/2 in Chronic Spontaneous Urticaria (CSU), and early-2025 top-line results from the povorcitinib Phase 3 trial in Hidradenitis Suppurativa (HS), all of which are expected to elucidate the potential for longer-term growth and compensate for the anticipated loss of exclusivity for Jakafi.
Here are the latest investment ratings and price targets for $Incyte (INCY.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月31日，多家华尔街大行更新了$因塞特 (INCY.US)$的评级，目标价介于80美元至97美元。
花旗分析师David Lebowitz维持买入评级，并将目标价从92美元上调至97美元。
TD Cowen分析师Marc Frahm维持买入评级，维持目标价80美元。
奥本海默控股分析师Jay Olson维持买入评级，并将目标价从81美元上调至82美元。
储亿银行分析师Srikripa Devarakonda维持持有评级。
JMP Securities分析师Reni Benjamin维持持有评级。
此外，综合报道，$因塞特 (INCY.US)$近期主要分析师观点如下：
因塞特第三季度的业绩表现超过预期，营业收入在Jakafi和Opzelura等必不可少的主要业务板块的持续增长推动下实现。坚实的商业表现、减少对Jakafi竞争对手的担忧以及具有多重机会的强劲管线加强了公司的基本叙事。
该公司此前对来自骨髓纤维化肿瘤的Jakafi的竞争压力持有保留意见，但承认当前强劲的持续需求表明风险已减少。他们还注意到，Opzelura的持续增长带来了乐观情绪，包括其扩展至儿童特应性皮炎的潜力。
该公司展示了强劲的商业季度，展示了其核心业务的韧性和实力，尽管季节性挑战和竞争压力存在。预计这种表现将维持势头，并随着公司接近2025财年上半年的几项重要更新而增强投资者情绪。
公司取得了营业收入的超额，并提供了持续稳定到改善的FY24指导。尽管对Jakafi的预期受到减少的Heme/Oncology板块投影的抵消，但公司的长期前景仍不确定，特别是考虑到预计在2028年Jakafi专利权到期后，管线对营业收入的影响。
因塞特展现出令人印象深刻的第三季度业绩，通过Jakafi和Opzelura推动的强劲营业收入超过预期，加上值得赞赏的底线。鉴于这种强劲的商业执行，公司提高了FY24的预测，暗示Jakafi有望在Q4实现出色的销售业绩，以及在随后财年实现年同比6%的扩张。预计行业焦点将转向管线项目，因为即将到来的多项催化剂在眼前，包括LIMBER项目的更新、慢性自发性荨麻疹(MRGPRX2)第1/2期的概念验证数据，以及Hidradenitis Suppurativa(HS)中povorcitinib第3期试验的2025年初营业收入结果，这些都有望阐明长期增长潜力并对Jakafi预期的专利权失效进行补偿。
以下为今日5位分析师对$因塞特 (INCY.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
